BIA
RETA

Bell Investment Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bell Investment Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6
Closed – – 2022
2022
Q2 		$0 Buy
+6
New +$179 ﹤0.01% 1866
2021
Q4 		$0 Sell
11
-4
-27% -$310 ﹤0.01% 1986
2021
Q3 		$2K Buy
+15
New +$1.76K ﹤0.01% 1207

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bell Investment Advisors's RETA Position: Q3 2022 in Review

Bell Investment Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 6 shares.

Bell Investment Advisors first reported a position in RETA in Q3 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

  • Bell Investment Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
  • Bell Investment Advisors sold 6 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022.
  • Bell Investment Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2021 and held it in 3 quarters.
  • Bell Investment Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on Bell Investment Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.